EP2184984A4 - Derivatives of n-(arylamino) sulfonamides including polymorphs as inhibitors of mek as well as compositions, methods of use and methods for preparing the same - Google Patents

Derivatives of n-(arylamino) sulfonamides including polymorphs as inhibitors of mek as well as compositions, methods of use and methods for preparing the same

Info

Publication number: EP2184984A4
Authority: EP; European Patent Office
Prior art keywords: methods; arylamino; mek; inhibitors; derivatives
Prior art date: 2007-07-30
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Ceased

Application number

EP08796733.7A

Other languages

German (de)

French (fr)

Other versions

EP2184984A1 (en

Inventor

Jean-Michel Vernier

Colin Edward Rowlings

Jean-Luc Girardet

Stuart Dimock

Barry Quart

Jeffrey N Miner

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Ardea Biociences Inc

Original Assignee

Ardea Biociences Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-07-30

Filing date

2008-07-28

Publication date

2013-07-24

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40304796&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP2184984(A4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2007-07-30 Priority claimed from US11/830,733 external-priority patent/US8101799B2/en

2008-07-28 Application filed by Ardea Biociences Inc filed Critical Ardea Biociences Inc

2010-05-19 Publication of EP2184984A1 publication Critical patent/EP2184984A1/en

2013-07-24 Publication of EP2184984A4 publication Critical patent/EP2184984A4/en

Status Ceased legal-status Critical Current

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N41/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a sulfur atom bound to a hetero atom
- A01N41/02—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a sulfur atom bound to a hetero atom containing a sulfur-to-oxygen double bond
- A01N41/04—Sulfonic acids; Derivatives thereof
- A01N41/06—Sulfonic acid amides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
- C07C311/28—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring

EP08796733.7A 2007-07-30 2008-07-28 Derivatives of n-(arylamino) sulfonamides including polymorphs as inhibitors of mek as well as compositions, methods of use and methods for preparing the same Ceased EP2184984A4 (en)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US11/830,733 US8101799B2 (en)	2005-07-21	2007-07-30	Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK
US3446608P	2008-03-06	2008-03-06
US3446408P	2008-03-06	2008-03-06
US4488608P	2008-04-14	2008-04-14
PCT/US2008/071392 WO2009018233A1 (en)	2007-07-30	2008-07-28	Derivatives of n-(arylamino) sulfonamides including polymorphs as inhibitors of mek as well as compositions, methods of use and methods for preparing the same

Publications (2)

Publication Number	Publication Date
EP2184984A1 EP2184984A1 (en)	2010-05-19
EP2184984A4 true EP2184984A4 (en)	2013-07-24

Family

ID=40304796

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP08796733.7A Ceased EP2184984A4 (en)	2007-07-30	2008-07-28	Derivatives of n-(arylamino) sulfonamides including polymorphs as inhibitors of mek as well as compositions, methods of use and methods for preparing the same

Country Status (23)

Country	Link
EP (1)	EP2184984A4 (en)
JP (3)	JP2010535232A (en)
KR (3)	KR20100092424A (en)
CN (2)	CN101808516B (en)
AP (1)	AP2817A (en)
AU (2)	AU2008282338B2 (en)
BR (1)	BRPI0815659A2 (en)
CA (1)	CA2693390C (en)
CO (1)	CO6470808A2 (en)
CR (1)	CR11244A (en)
DO (1)	DOP2010000045A (en)
EA (2)	EA020624B1 (en)
EC (1)	ECSP109910A (en)
HK (1)	HK1147396A1 (en)
HN (1)	HN2010000203A (en)
IL (1)	IL203296A (en)
MA (1)	MA31881B1 (en)
MX (1)	MX2010001244A (en)
NZ (1)	NZ582929A (en)
PH (1)	PH12015501914A1 (en)
SV (1)	SV2010003469A (en)
TN (1)	TN2010000049A1 (en)
WO (1)	WO2009018233A1 (en)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7723477B2 (en)	2005-10-31	2010-05-25	Oncomed Pharmaceuticals, Inc.	Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
EP2291350A4 (en) *	2008-04-14	2012-09-19	Ardea Biosciences Inc	Compositions and methods for preparing and using same
TR201818979T4 (en) *	2008-09-09	2019-01-21	Hoffmann La Roche	Polymorphs of acyl sulfonamides.
AU2009296246B2 (en)	2008-09-26	2015-07-30	Oncomed Pharmaceuticals, Inc.	Frizzled-binding agents and uses thereof
UY32486A (en) *	2009-03-11	2010-10-29	Ardea Biosciences Inc	TREATMENT OF CANCER CANCER
BRPI1009448A2 (en) *	2009-03-11	2016-03-01	Ardea Biosciences Inc	pharmaceutical combinations comprising edea119 / bay 869766 for the treatment of specific cancers
KR20120094165A (en)	2009-10-13	2012-08-23	알로스팀 테라퓨틱스 엘엘씨	Novel mek inhibitors, useful in the treatment of diseases
US8962606B2 (en) *	2009-10-21	2015-02-24	Bayer Intellectual Property Gmbh	Substituted benzosulphonamides
TWI535445B (en)	2010-01-12	2016-06-01	安可美德藥物股份有限公司	Wnt antagonists and methods of treatment and screening
CN102020651B (en)	2010-11-02	2012-07-18	北京赛林泰医药技术有限公司	6-aryl amino pyridone formamide MEK (methyl ethyl ketone) inhibitor
CN102649773A (en) *	2011-02-23	2012-08-29	苏州波锐生物医药科技有限公司	Amino aromatic hydrocarbon compound and application thereof to preparation of medicine for resisting malignant tumor
KR102196424B1 (en) *	2011-04-28	2020-12-30	슬로안-케테링인스티튜트퍼캔서리서치	Hsp90 combination therapy
MX362823B (en) *	2011-05-27	2019-02-18	Ardea Biosciences Inc Star	Chiral synthesis of n-{3,4-difluoro-2-[(2-fluoro-4-iodophenyl)ami no]-6-methoxyphenyl}-1-[2,3-dihydroxy-propyl]cyclopropanesulfona mides.
EP2788378A4 (en) *	2011-12-09	2015-09-09	Oncomed Pharm Inc	Combination therapy for treatment of cancer
WO2013109142A1 (en)	2012-01-16	2013-07-25	Stichting Het Nederlands Kanker Instituut	Combined pdk and mapk/erk pathway inhibition in neoplasia
CN104394855A (en) *	2012-05-31	2015-03-04	拜耳医药股份有限公司	Biomarkers for determining effective response of treatments of hepatocellular carcinoma (HCC) patients
NZ702548A (en)	2012-06-04	2015-11-27	Pharmacyclics Llc	Crystalline forms of a bruton’s tyrosine kinase inhibitor
LT3702351T (en) *	2012-10-19	2024-01-10	Array Biopharma, Inc.	Formulation comprising a mek inhibitor
WO2014071183A1 (en)	2012-11-02	2014-05-08	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Method of reducing adverse effects in a cancer patient undergoing treatment with a mek inhibitor
CN105073195A (en)	2013-02-04	2015-11-18	昂科梅德制药有限公司	Methods and monitoring of treatment with a Wnt pathway inhibitor
EP2848246A1 (en)	2013-09-13	2015-03-18	Bayer Pharma Aktiengesellschaft	Pharmaceutical compositions containing refametinib
WO2015041534A1 (en)	2013-09-20	2015-03-26	Stichting Het Nederlands Kanker Instituut	P90rsk in combination with raf/erk/mek
WO2015041533A1 (en)	2013-09-20	2015-03-26	Stichting Het Nederlands Kanker Instituut	Rock in combination with mapk-pathway
WO2015156674A2 (en)	2014-04-10	2015-10-15	Stichting Het Nederlands Kanker Instituut	Method for treating cancer
WO2015178770A1 (en)	2014-05-19	2015-11-26	Stichting Het Nederlands Kanker Instituut	Compositions for cancer treatment
EP3185900A4 (en) *	2014-08-25	2018-05-02	Aimmune Therapeutics, Inc.	Egg protein formulations and methods of manufacture thereof
BR122023020985A2 (en)	2015-03-03	2023-12-26	Pharmacyclics Llc	SOLID TABLET FORMULATION OF A BRUTON'S TYROSINE KINASE INHIBITOR
CA3067044A1 (en) *	2017-06-16	2018-12-20	Beta Pharma, Inc.	Pharmaceutical formulations of n-(2-(2-(dimethylamino)ethoxy)-4-methoxy-5-((4-(1-methyl-1h-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide and salts thereof
AU2020242287A1 (en)	2019-03-21	2021-09-02	INSERM (Institut National de la Santé et de la Recherche Médicale)	A Dbait molecule in combination with kinase inhibitor for the treatment of cancer
US20220401436A1 (en)	2019-11-08	2022-12-22	INSERM (Institute National de la Santé et de la Recherche Médicale)	Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en)	2020-01-22	2021-07-29	Onxeo	Novel dbait molecule and its use

Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2007014011A2 (en) *	2005-07-21	2007-02-01	Ardea Biosciences, Inc.	N-(arylamino)-sulfonamide inhibitors of mek

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5162117A (en) *	1991-11-22	1992-11-10	Schering Corporation	Controlled release flutamide composition
JP2575590B2 (en) *	1992-07-31	1997-01-29	塩野義製薬株式会社	Triazolylthiomethylthiocephalosporin hydrochloride and its hydrate crystals and their preparation
DK0656887T3 (en) *	1992-08-25	1999-07-05	Searle & Co	Hydroxyethylaminosulfonamides for use as inhibitors of retroviral proteases
US7115632B1 (en) *	1999-05-12	2006-10-03	G. D. Searle & Co.	Sulfonyl aryl or heteroaryl hydroxamic acid compounds
CZ20012528A3 (en) *	1999-01-13	2002-06-12	Warner-Lambert Company	1-Heterocyclically substituted diaryl amines, pharmaceutical compositions based thereon and treatment methods
GB0003224D0 (en) *	2000-02-11	2000-04-05	Glaxo Group Ltd	Chemical compounds
US7235567B2 (en) *	2000-06-15	2007-06-26	Schering Corporation	Crystalline polymorph of a bisulfate salt of a thrombin receptor antagonist
WO2003026574A2 (en) *	2001-09-24	2003-04-03	Au Jessie L-S	Methods and compositions to determine the chemosensitizing dose of suramin used in combination therapy
KR20050040907A (en) *	2002-07-17	2005-05-03	타이탄 파머슈티컬즈 인코퍼레이티드	Combination of chemotherapeutic drugs for increasing antitumor activity
JP2005535688A (en) *	2002-07-30	2005-11-24	ツェンタリスゲゼルシャフトミットベシュレンクテルハフツング	Use of alkylphosphocholines in combination with antitumor drugs
BRPI0607537A2 (en) *	2005-04-12	2009-09-15	Elan Pharma Int Ltd	nanoparticulate quinazoline derivative formulations
WO2006115154A1 (en) *	2005-04-22	2006-11-02	Kissei Pharmaceutical Co., Ltd.	Crystal polymorphism of 4’-{2-[(1s,2r)-2-hydroxy-2-(4-hydroxyphenyl)-1-methylethylamino]ethoxy}-3-isopropyl-3’,5’-dimethylbiphenylcarboxylic acid hydrochloride
JP2007099763A (en) *	2005-09-08	2007-04-19	Toyama Chem Co Ltd	New crystal of piperacillin sodium-1 hydrate and method for producing the same
TW200800150A (en) *	2005-12-21	2008-01-01	Organon Nv	Compounds with medicinal effects due to interaction with the glucocorticoid receptor

2008
- 2008-07-28 CA CA2693390A patent/CA2693390C/en not_active Expired - Fee Related
- 2008-07-28 EP EP08796733.7A patent/EP2184984A4/en not_active Ceased
- 2008-07-28 BR BRPI0815659-0A2A patent/BRPI0815659A2/en not_active Application Discontinuation
- 2008-07-28 MX MX2010001244A patent/MX2010001244A/en active IP Right Grant
- 2008-07-28 AU AU2008282338A patent/AU2008282338B2/en not_active Ceased
- 2008-07-28 WO PCT/US2008/071392 patent/WO2009018233A1/en active Application Filing
- 2008-07-28 KR KR1020107004742A patent/KR20100092424A/en active Search and Examination
- 2008-07-28 CN CN2008801088296A patent/CN101808516B/en not_active Expired - Fee Related
- 2008-07-28 EA EA201000268A patent/EA020624B1/en not_active IP Right Cessation
- 2008-07-28 CN CN201310317815.8A patent/CN103479604B/en not_active Expired - Fee Related
- 2008-07-28 JP JP2010520118A patent/JP2010535232A/en active Pending
- 2008-07-28 KR KR1020157020493A patent/KR20150091434A/en not_active Application Discontinuation
- 2008-07-28 NZ NZ582929A patent/NZ582929A/en not_active IP Right Cessation
- 2008-07-28 AP AP2010005134A patent/AP2817A/en active
- 2008-07-28 EA EA201400552A patent/EA032294B1/en not_active IP Right Cessation
- 2008-07-28 KR KR1020147017261A patent/KR20140098185A/en not_active Application Discontinuation
2010
- 2010-01-13 IL IL203296A patent/IL203296A/en not_active IP Right Cessation
- 2010-01-29 TN TNP2010000049A patent/TN2010000049A1/en unknown
- 2010-01-29 SV SV2010003469A patent/SV2010003469A/en unknown
- 2010-01-29 HN HN2010000203A patent/HN2010000203A/en unknown
- 2010-01-29 DO DO2010000045A patent/DOP2010000045A/en unknown
- 2010-01-29 CO CO10009526A patent/CO6470808A2/en not_active Application Discontinuation
- 2010-01-29 EC EC2010009910A patent/ECSP109910A/en unknown
- 2010-01-29 CR CR11244A patent/CR11244A/en not_active Application Discontinuation
- 2010-02-19 MA MA32636A patent/MA31881B1/en unknown
2011
- 2011-02-18 HK HK11101625.8A patent/HK1147396A1/en not_active IP Right Cessation
2014
- 2014-11-14 JP JP2014231450A patent/JP6309880B2/en not_active Expired - Fee Related
2015
- 2015-01-28 AU AU2015200390A patent/AU2015200390B2/en not_active Ceased
- 2015-08-28 PH PH12015501914A patent/PH12015501914A1/en unknown
2017
- 2017-02-03 JP JP2017018477A patent/JP2017125021A/en active Pending

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2007014011A2 (en) *	2005-07-21	2007-02-01	Ardea Biosciences, Inc.	N-(arylamino)-sulfonamide inhibitors of mek

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CAIRA M R: "CRYSTALLINE POLYMORPHISM OF ORGANIC COMPOUNDS", TOPICS IN CURRENT CHEMISTRY, SPRINGER, BERLIN, DE, vol. 198, 1 January 1998 (1998-01-01), pages 163 - 208, XP001156954, ISSN: 0340-1022, ISBN: 978-3-540-36760-4, DOI: 10.1007/3-540-69178-2_5 *
See also references of WO2009018233A1 *

Also Published As

Publication number	Publication date
KR20100092424A (en)	2010-08-20
AP2817A (en)	2013-12-31
CA2693390C (en)	2017-01-17
IL203296A (en)	2017-06-29
SV2010003469A (en)	2010-04-30
MX2010001244A (en)	2010-08-31
CN101808516A (en)	2010-08-18
JP2010535232A (en)	2010-11-18
ECSP109910A (en)	2010-04-30
WO2009018233A1 (en)	2009-02-05
AU2008282338A1 (en)	2009-02-05
TN2010000049A1 (en)	2011-09-26
CA2693390A1 (en)	2009-02-05
EP2184984A1 (en)	2010-05-19
CO6470808A2 (en)	2012-06-29
KR20150091434A (en)	2015-08-10
HN2010000203A (en)	2012-11-19
DOP2010000045A (en)	2010-10-31
JP2017125021A (en)	2017-07-20
EA032294B1 (en)	2019-05-31
CN103479604A (en)	2014-01-01
EA201000268A1 (en)	2010-08-30
EA020624B1 (en)	2014-12-30
CN101808516B (en)	2013-08-28
BRPI0815659A2 (en)	2014-09-30
HK1147396A1 (en)	2011-08-12
CN103479604B (en)	2016-08-10
JP2015078199A (en)	2015-04-23
CR11244A (en)	2010-05-20
NZ582929A (en)	2012-03-30
AP2010005134A0 (en)	2010-02-28
EA201400552A1 (en)	2014-09-30
PH12015501914A1 (en)	2017-07-31
MA31881B1 (en)	2010-12-01
JP6309880B2 (en)	2018-04-11
KR20140098185A (en)	2014-08-07
AU2008282338B2 (en)	2015-02-12
AU2015200390B2 (en)	2017-02-23

Legal Events

Date	Code	Title	Description
2010-04-16	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2010-05-19	17P	Request for examination filed	Effective date: 20100301
2010-05-19	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR
2010-05-19	AX	Request for extension of the european patent	Extension state: AL BA MK RS
2010-06-09	RAX	Requested extension states of the european patent have changed	Extension state: MK Payment date: 20100503 Extension state: BA Payment date: 20100503 Extension state: AL Payment date: 20100503 Extension state: RS Payment date: 20100503
2013-07-24	A4	Supplementary search report drawn up and despatched	Effective date: 20130621
2013-07-24	RIC1	Information provided on ipc code assigned before grant	Ipc: A61K 31/18 20060101ALI20130617BHEP Ipc: A01N 41/06 20060101AFI20130617BHEP
2015-07-15	RAP1	Party data changed (applicant data changed or rights of an application transferred)	Owner name: ARDEA BIOSCIENCES, INC.
2015-07-29	17Q	First examination report despatched	Effective date: 20150626
2018-04-25	REG	Reference to a national code	Ref country code: DE Ref legal event code: R003
2018-09-14	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED
2018-10-17	18R	Application refused	Effective date: 20180425

Publication	Publication Date	Title
HK1147396A1 (en)	2011-08-12	Derivatives of n-(arylamino) sulfonamides including polymorphs as inhibitors of mek as well as compositions, methods of use and methods for preparing the same
AU2015200390A1 (en)	2015-02-19	Derivatives of N-(arylamino) sulfonamides including polymorphs as inhibitors of MEK as well as compositions, methods of use and methods for preparing the same
IL222698A0 (en)	2012-12-31	Benzazole derivatives, compositions, and methods of use as b- secretase inhibitors
HK1125631A1 (en)	2009-08-14	Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors
PH12015501484A1 (en)	2017-06-05	Heteroaryl compounds and uses thereof
ZA201209297B (en)	2014-09-25	5,6-dihydro-2h-[1,4]oxazin-3-yl-amine derivatives useful as inhibitors of beta-secretase (bace)
WO2011032169A3 (en)	2011-07-21	Pharmaceutical compositions and formulations including inhibitors of the pleckstrin homology domain and methods for using same
IL204437A (en)	2013-09-30	Cyclopropyl aryl amide derivatives and uses thereof
HK1164876A1 (en)	2012-09-28	1, 3-disubstituted imidazolidin-2-one derivatives as inhibitors of cyp 17
DK3461503T3 (en)	2022-02-14	METHODS FOR THE ADMINISTRATION OF TETRAHYDROBIOPTERIN, ASSOCIATED COMPOSITIONS AND MEASUREMENT PROCEDURES
IL218669A (en)	2016-08-31	Compounds effective as xanthine oxidase inhibitors, method for preparing the same and pharmaceutical compositions containing the same
ZA200905671B (en)	2010-10-27	Heterocyclic compounds, compositions comprising them and methods of their use
MX2010003495A (en)	2010-04-21	Quinazolinedione derivatives, preparation thereof and therapeutic uses thereof.
HRP20130585T1 (en)	2013-07-31	Alkylthiazol carbamate derivatives, preparation thereof and their use as faah inhibitors
EP1954685A4 (en)	2009-11-11	Furoxan compounds, compositions and methods of use
ZA200908612B (en)	2010-11-24	1,3-dihydroimidazole-2-thione derivatives as inhibitors of dopamine-beta-hydroxylase
WO2009007535A3 (en)	2009-04-09	Derivatives of 7-alkynyl-1,8-naphthyridones, preparation method thereof and use of same in therapeutics
IL206153A0 (en)	2010-12-30	Rna antagonist compounds for the modulation of pik3ca compositions comprising the same and uses thereof
IL179076A0 (en)	2007-03-08	Azasugasr derivatives, heparanase inhibitors, method for preparing same, compositions containing same, use thereof
EP2320738A4 (en)	2011-08-24	Substituted aminothiazole derivatives, pharmaceutical compositions, and methods of use
IL200795A0 (en)	2010-05-17	Prodrug compounds of (+)3-hydroxymorphinan, compositions comprising the same and use thereof
TH0901000961A (en)	2016-04-07	N-(arylamino)sulfonamide derivatives including polymorphs as MEK inhibitors and constituents, methods of use. and methods for preparing the same substances
EP2213650A4 (en)	2014-04-02	Substituted diphenylamines as inhibitors of reverse transcriptase, process of preparing them and use thereof
TH148538B (en)	2016-04-07	Derivatives of N- (aryl amino) sulfonamides including polymorphs as inhibitors of MEK and their constituents, method of application. And methods for preparing the same substance
WO2010077734A3 (en)	2010-09-23	Novel antiviral compounds, compositions, and methods of use